Alembic Pharmaceuticals Share Price

Please find attached Audio Recording of Investor Call.

• BSE India
• 10 minutes 14 seconds ago

Conference Call with Alembic Pharmaceuticals Management and Analysts on Q2FY27 Performance and Outlook. Listen to the <a href="https://youtu.be/K5RLAGNSgz0">full earnings transcript</a>. <br>

• Trendlyne
• 15 minutes 34 seconds ago

<h3><span style="font-size:16px;"><strong>Pharmaceuticals company Alembic Pharmaceuticals announced Q2FY27 results</strong></span></h3> <p><strong>Consolidated Financial Highlights<!--TgQPHd|||[[2,[null,null,1,null,null,null,null,null,null,null,null,null,[351768,null,0]],[],null,1]]-->:</strong><br /> <!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></p> <ul data-complete="true" data-hveid="CAAICBAA" data-processed="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="wiLEJc#NS0kde" jsuid="wss2Wb_1k"> <li data-complete="true" data-hveid="CAAICBAF" data-processed="true" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="wss2Wb_1w">Total income:<!--TgQPHd|||[]--> For Q2FY27, Consolidated Total income stood at Rs 2,618.59 crore, registering a YoY increase of 36.59% and a QoQ increase of 20.97%. For H1FY27, Consolidated Total income was Rs 4,783.29 crore, showing a YoY growth of 31.62% compared to Rs 3,634.28 crore in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICBAF" data-processed="true" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="wss2Wb_1w">Revenue from operations:<!--TgQPHd|||[]--> Consolidated Revenue from operations during Q2FY27 was recorded at Rs 2,603.48 crore, marking a YoY increase of 36.30% and a QoQ growth of 21.11%. For H1FY27, Consolidated Revenue from operations aggregated to Rs 4,753.25 crore, rising 31.27% YoY from Rs 3,620.87 crore in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICBAF" data-processed="true" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="wss2Wb_1w">Profit Before Tax (PBT):<!--TgQPHd|||[]--> Consolidated PBT for Q2FY27 reached Rs 437.95 crore, up by 95.76% YoY and up by 97.40% QoQ. For H1FY27, Consolidated PBT stood at Rs 659.81 crore, reflecting a YoY growth of 59.44% over Rs 413.82 crore in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICBAF" data-processed="true" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="wss2Wb_1w">Profit After Tax (PAT):<!--TgQPHd|||[]--> Consolidated PAT for Q2FY27 stood at Rs 335.17 crore, increasing by 81.46% YoY and expanding 93.66% QoQ. For H1FY27, Consolidated PAT reached Rs 508.23 crore, growing 49.88% YoY from Rs 339.09 crore in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICBAF" data-processed="true" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="wss2Wb_1w">Earnings Per Share (EPS):<!--TgQPHd|||[]--> Consolidated EPS for Q2FY27 was recorded at Rs 17.05, representing an 81.38% increase YoY and a 93.75% increase QoQ. For H1FY27, Consolidated EPS reached Rs 25.86, showing a YoY increase of 49.91% compared to Rs 17.25 in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> </ul> <p><!--TgQPHd|||[]--></p> <p><strong>Standalone Financial Highlights:</strong><!--TgQPHd|||[[2,[null,null,1,null,null,null,null,null,null,null,null,null,[351768,null,0]],[],null,1]]--><br /> <!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></p> <ul data-complete="true" data-hveid="CAAICBAA" data-processed="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="wiLEJc#NS0kde" jsuid="wss2Wb_1k"> <li data-complete="true" data-hveid="CAAICBAF" data-processed="true" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="wss2Wb_1w">Total income:<!--TgQPHd|||[]--> For Q2FY27, Standalone Total income reached Rs 2,416.07 crore, indicating a YoY increase of 33.65% and a QoQ rise of 28.37%. For H1FY27, Standalone Total income stood at Rs 4,298.17 crore, climbing 29.87% YoY from Rs 3,309.69 crore in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICBAF" data-processed="true" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="wss2Wb_1w">Revenue from operations:<!--TgQPHd|||[]--> Standalone Revenue from operations for Q2FY27 stood at Rs 2,391.65 crore, a YoY growth of 33.15% and a QoQ growth of 28.03%. For H1FY27, Standalone Revenue from operations was Rs 4,259.72 crore, showing a change of 29.46% YoY against Rs 3,290.41 crore in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICBAF" data-processed="true" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="wss2Wb_1w">Profit Before Tax (PBT):<!--TgQPHd|||[]--> Standalone PBT for Q2FY27 achieved Rs 534.81 crore, escalating by 147.20% YoY and 108.99% QoQ. For H1FY27, Standalone PBT stood at Rs 790.72 crore, increasing 131.29% YoY over Rs 341.87 crore in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICBAF" data-processed="true" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="wss2Wb_1w">Profit After Tax (PAT):<!--TgQPHd|||[]--> Standalone PAT during Q2FY27 was reported at Rs 409.36 crore, a YoY improvement of 128.23% and a QoQ growth of 107.84%. For H1FY27, Standalone PAT stood at Rs 606.32 crore, exhibiting a growth of 114.34% YoY compared to Rs 282.88 crore in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICBAF" data-processed="true" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="wss2Wb_1w">Earnings Per Share (EPS):<span style="display: none;"> </span><!--TgQPHd|||[]--> Standalone EPS for Q2FY27 stood at Rs 20.83, reflecting a YoY growth of 128.40% and a QoQ expansion of 107.88%. For H1FY27, Standalone EPS arrived at Rs 30.85, a YoY increase of 114.38% from Rs 14.39 in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> </ul> <p><strong>Pranav Amin, Managing Director, Alembic Pharmaceuticals, said:</strong> “We delivered another quarter of strong, broad-based growth and improved profitability, reflecting consistent execution across markets. Our US business delivered an exceptional performance, driven by strong volume growth and new launches, while India regained momentum as Ex-US and API continued their growth trajectories. In India Branded, improving momentum in chronic therapies is strengthening the quality of growth, while in US Branded, we are encouraged by the traction building across our existing portfolio. Following a strong first half, we are well positioned to sustain growth and create long-term value for all our stakeholders.”</p> <p><a class="lb" href="/get-document/post/pdf/5929143/" target="_blank">Result PDF</a></p>

• Trendlyne
• 3 hours 46 minutes ago